KYMR · Kymera Therapeutics, Inc.
$117.39
+2.97 (+2.60%)
At close · Aug 14
Market Cap
$9.76B
Shares
83.15M
Kymera Therapeutics, Inc. Earnings Call Transcripts
Every quarterly earnings call for Kymera Therapeutics, Inc. (KYMR) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼53%
$9.55M
−$43.00M
'22 Q3
22-11-03
▲5.7%
$16.14M
−$34.87M
'22 Q4
23-01-10
▼1.6%
$9.47M
−$40.93M
'23 Q1
23-05-04
▲43.4%
$16.51M
−$38.80M
'23 Q2
23-08-03
▼50.5%
$4.73M
−$52.87M
'23 Q3
23-11-02
▲196.7%
$47.88M
−$14.37M
'23 Q4
24-02-22
▲8.7%
$10.29M
−$48.56M
'24 Q1
24-05-02
▲55.3%
$25.65M
−$42.06M
'24 Q2
24-08-07
▼20.9%
$3.74M
−$62.49M
'24 Q3
24-10-31
▼84.6%
$7.39M
−$70.75M
'24 Q4
25-02-27
▲114.8%
$22.10M
−$65.58M
'25 Q1
25-05-09
▼55.3%
$11.48M
−$76.61M
'25 Q2
25-08-11
▼26.1%
$2.76M
−$82.17M
'25 Q3
25-11-04
▼61.2%
$2.87M
−$86.98M
'25 Q4
26-02-26
▲55.5%
$34.37M
−$69.23M
'26 Q1
26-04-30
LATEST
▲466.4%
$65.00M
−$61.21M
'26 Q2
26-08-05
Earnings call
FY26 · Q2
2026-08-05
Kymera Therapeutics, Inc. Q2 FY2026 Earnings Call
Revenue
$65.00M
▲ 466.4% YoY Diluted EPS
$-0.62
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Kymera Therapeutics, Inc. Q1 FY2026 Earnings Call
Revenue
$34.37M
▲ 55.5% YoY Diluted EPS
$-0.71
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-03-12
Barclays 28th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-26
Kymera Therapeutics, Inc. Q4 FY2025 Earnings Call
Confident tone
KT-579 IRF5 Degrader for Lupus
KT-621 STAT6 Degrader in Atopic Dermatitis and Asthma
Pipeline Expansion and New Development Candidate
Revenue
$2.87M*
▼ 61.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Kymera Therapeutics, Inc. Q3 FY2025 Earnings Call
Confident tone
KT-621 STAT6 program
BroADen Phase Ib data readout
Asthma and pediatric opportunity
Revenue
$2.76M
▼ 26.1% YoY Diluted EPS
$-0.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Kymera Therapeutics, Inc. Q2 FY2025 Earnings Call
Confident tone
KT-621 STAT6 program
Phase IIb dose selection and trial planning
Biomarker and clinical endpoint expectations
Revenue
$11.48M
▼ 55.3% YoY Diluted EPS
$-0.95
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Kymera Therapeutics, Inc. Q1 FY2025 Earnings Call
Confident tone
IRAF5 program introduction
Immunology opportunity and market
Clinical execution and milestones
Revenue
$22.10M
▲ 114.8% YoY Diluted EPS
$-0.82
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Kymera Therapeutics, Inc. Q4 FY2024 Earnings Call
Confident tone
STAT6 / KT-621 program
New immunology target / pipeline expansion
Clinical readout timing risks
Revenue
$7.39M*
▼ 84.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Kymera Therapeutics, Inc. Q3 FY2024 Earnings Call
Confident tone
KT-621 STAT6 degrader Phase 1
TYK2 program progression
Partnership considerations for STAT6
Revenue
$3.74M
▼ 20.9% YoY Diluted EPS
$-0.82
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Kymera Therapeutics, Inc. Q2 FY2024 Earnings Call
Confident tone
KT-621 / STAT6 program
KT-474 / IRAK4 program
Pipeline and platform
Revenue
$25.65M
▲ 55.3% YoY Diluted EPS
$-0.58
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Kymera Therapeutics, Inc. Q1 FY2024 Earnings Call
Confident tone
IRAK4 / KT-474 program
STAT6 degrader KT-621
TYK2 degrader KT-294
Revenue
$10.29M
▲ 8.7% YoY Diluted EPS
$-0.69
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Kymera Therapeutics, Inc. Q4 FY2023 Earnings Call
Confident tone
STAT6 degrader (KT-621)
IRAK4 / KT-474 program with Sanofi
TYK2 degrader (KT-294)
Revenue
$47.88M*
▲ 196.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Kymera Therapeutics, Inc. Q3 FY2023 Earnings Call
Revenue
$4.73M
▼ 50.5% YoY Diluted EPS
$-0.90
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Kymera Therapeutics, Inc. Q2 FY2023 Earnings Call
Revenue
$16.51M
▲ 43.4% YoY Diluted EPS
$-0.67
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Kymera Therapeutics, Inc. Q1 FY2023 Earnings Call
Revenue
$9.47M
▼ 1.6% YoY Diluted EPS
$-0.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-01-10
Kymera Therapeutics, Inc. Q4 FY2022 Earnings Call
Revenue
$16.14M*
▲ 5.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Kymera Therapeutics, Inc. Q3 FY2022 Earnings Call
Revenue
$9.55M
▼ 53% YoY Diluted EPS
$-0.79
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Kymera Therapeutics, Inc. Q2 FY2022 Earnings Call
Revenue
$11.51M
▼ 37.8% YoY Diluted EPS
$-0.78
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Kymera Therapeutics, Inc. Q1 FY2022 Earnings Call
Revenue
$9.62M
▼ 48.6% YoY Diluted EPS
$-0.71
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–20 of 20 earnings calls
Key facts
CIK
1815442
CUSIP
501575104
13F (30d)
272 filings
270 filers
Visit website
Investor relations